Market Access

Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.

A focus on medical affairs and medical science liaisons.

Pandemic-reinforced principles of successful drug launch.

In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.

A business framework for pricing and broader brand strategy.

Commercial-model shift demanding greater influence of these teams.

David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.

Identifying unique traits in patients is key to creating the most effective support programs.

Writing at the intersection of managed markets and the pharmaceutical industry.

On examination of the challenge and strategies, lack of adherence is in and of itself a preventable disease.

Winning in the 20s: How access needs to evolve.

Patient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.

Taking a closer look at the evolving legal treatment of coupons and copay accumulators.

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

If telehealth is here to stay, how is the industry adjusting?

How technology can maximize use of manufacturer copay and patient assistance programs.

The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.

A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.

Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.

Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.

Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.

A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.

While gene therapies continue to revolutionize healthcare, uncertainty from commercialization issues still looms large.

Amid pandemic, rely on the fundamentals.